Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4% - Time to Buy?

Key Points

• Syndax Pharmaceuticals' stock rose 4.4% to $14.04 during Thursday's trading, although trading volume was 80% lower than average.
• Analysts have given a consensus rating of "Moderate Buy" with a target price average of $36.91, despite varied individual ratings ranging from sell to strong buy.
• The company reported a significant revenue increase of 984.5% year-over-year, posting $37.96 million for the quarter, while beating EPS estimates.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report)'s share price was up 4.4% during mid-day trading on Thursday . The stock traded as high as $14.01 and last traded at $14.04. Approximately 449,627 shares traded hands during trading, a decline of 80% from the average daily volume of 2,224,287 shares. The stock had previously closed at $13.45.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SNDX shares. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. BTIG Research lifted their target price on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Scotiabank lifted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. UBS Group dropped their target price on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Finally, Guggenheim reiterated a "buy" rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.91.

Syndax Pharmaceuticals Trading Up 6.6%

The stock has a market capitalization of $1.24 billion, a P/E ratio of -3.69 and a beta of 0.74. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The stock's fifty day moving average price is $10.20 and its two-hundred day moving average price is $11.88.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company had revenue of $37.96 million during the quarter, compared to analyst estimates of $26.64 million. During the same period in the prior year, the business posted ($0.80) EPS. The firm's revenue was up 984.5% compared to the same quarter last year. Equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 7,534 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total transaction of $69,990.86. Following the completion of the sale, the chief executive officer directly owned 298,661 shares in the company, valued at $2,774,560.69. This represents a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Soleus Capital Management L.P. lifted its position in shares of Syndax Pharmaceuticals by 128.4% in the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after purchasing an additional 1,401,016 shares during the period. Stempoint Capital LP lifted its position in shares of Syndax Pharmaceuticals by 48.4% in the 2nd quarter. Stempoint Capital LP now owns 2,372,634 shares of the company's stock worth $22,220,000 after purchasing an additional 774,040 shares during the period. Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 14.5% in the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company's stock worth $22,098,000 after purchasing an additional 298,272 shares during the period. Geode Capital Management LLC lifted its position in shares of Syndax Pharmaceuticals by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,049,350 shares of the company's stock worth $19,195,000 after purchasing an additional 26,365 shares during the period. Finally, Qube Research & Technologies Ltd lifted its position in shares of Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company's stock worth $15,601,000 after purchasing an additional 831,067 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.